Get the Stockscreener App
4.27
26.71%
0.90
After Hours:
4.26
-0.010
-0.23%
Ironwood Pharmaceuticals Inc stock is traded at $4.27, with a volume of 84.83M.
It is up +26.71% in the last 24 hours and up +22.00% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$3.37
Open:
$4.595
24h Volume:
84.83M
Relative Volume:
23.55
Market Cap:
$694.64M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
106.75
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
+33.44%
1M Performance:
+22.00%
6M Performance:
+477.26%
1Y Performance:
-1.39%
1-Day Range:
$4.20
$5.78
1-Week Range:
$3.11
$5.78
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.27 | 548.23M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
125.92 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.00 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals Surges on Linzess Sales Boost - StocksToTrade
Ironwood Pharma leaps on 2025/2026 guidance - The Pharma Letter
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Stock soars at Boston biotech after it cuts price of IBS drug - The Business Journals
Ironwood Finds a New Floor as LINZESS Net Pricing Turns Into a Growth Lever - Investing.com
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeline Updates - GuruFocus
Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance - Quiver Quantitative
Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 - Barron's
Ironwood Pharmaceuticals stock soars on strong 2026 guidance By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals stock soars on strong 2026 guidance - Investing.com
Stock Traders Buy High Volume of Ironwood Pharmaceuticals Call Options (NASDAQ:IRWD) - MarketBeat
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - Seeking Alpha
Ironwood Reaffirms FY2025 Revenue Outlook, Sees Growth In FY2026; Stock Surges - RTTNews
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month HighHere's Why - MarketBeat
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
Ironwood Pharma Stock Rallies On Strong 2026 OutlookIronwood Pharmaceuticals (NASDAQ:IRWD) - Benzinga
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Stocktwits
Ironwood’s Recent Move: A Catalyst for Change? - timothysykes.com
Why Is IRWD Stock Soaring Over 30% Premarket? 2026 Revenue Outlook Beats Estimates - Tokenist
Ironwood (IRWD) Focuses on Financial Growth and Drug Development - GuruFocus
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Year 2025 and Provides Earnings Guidance for Year 2026 - marketscreener.com
Ironwood Pharmaceuticals (IRWD) Projects Strong Revenue Growth f - GuruFocus
Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess - MSN
Ironwood Pharma Provides FY26 Outlook, Maintains Full Year Outlook - Nasdaq
Ironwood forecasts 2026 LINZESS sales to exceed $1.1 billion - Investing.com
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - TradingView — Track All Markets
Ironwood surges after forecasting Linzess' reentry into blockbuster territory - FirstWord Pharma
Ironwood Pharmaceuticals expresses gratitude and drives GI health progress - Traders Union
Why is Ironwood (IRWD) up 24.9% since last earnings report? - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 4.8%Still a Buy? - MarketBeat
Ironwood Pharma (NASDAQ:IRWD) Nasdaq composite Biotech Watch - Kalkine Media
Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Ironwood Pharmaceuticals' VectivBio Settles Ferring Lawsuit Through License Amendment - marketscreener.com
Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property - The Business Journals
Ironwood gains after settling Ferring lawsuit (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharmaceuticals amends license deal with Ferring, settles litigation - Investing.com
Ironwood Pharmaceuticals amends license deal with Ferring, settles litigation By Investing.com - Investing.com UK
Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to S&P Biotechnology Select Industry Index - marketscreener.com
How Ironwood Pharmaceuticals Inc. (I76) stock reacts to Fed tighteningOil Prices & Free Accurate Trade Setup Notifications - Улправда
Geopolitics Watch: Why Ironwood Pharmaceuticals Inc. stock is rated strong buyAnalyst Downgrade & Stepwise Trade Signal Guides - Улправда
Why Ironwood Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Update & High Accuracy Trade Signal Alerts - Улправда
Ironwood Pharmaceuticals Earnings Notes - Trefis
Published on: 2025-12-19 06:52:33 - Улправда
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7%Here's Why - MarketBeat
What drives Ironwood Pharmaceuticals Inc stock priceMarket Entry Points & High Yield Portfolio Growth - earlytimes.in
Ironwood Pharmaceuticals (IRWD) director and 10% owner reports new share grant - Stock Titan
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):